The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke.
BACKGROUND
Inflammation is increasingly recognised as playing a central role in atherosclerosis, and peripheral blood markers of inflammation have been associated with incident and recurrent cardiac events. The relationship of these potentially modifiable risk markers to prognosis after ischaemic stroke is less clear. The Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) study will address hypotheses related to the role of inflammatory markers in secondary stroke prevention in an efficient manner using the well-established framework of the Secondary Prevention of Small Subcortical Strokes (SPS3) trial (NCT00059306).


METHODS
SPS3 is an ongoing Phase III multicentre secondary prevention trial focused on preventing recurrent stroke in patients with small vessel ischaemic stroke, or lacunes. In SPS3, patients are assigned in a factorial design to aspirin vs. aspirin plus clopidogrel, and to usual vs. aggressive blood pressure targets. The purpose of LIMITS is to determine whether serum levels of inflammatory markers - including high-sensitivity C-reactive protein, serum amyloid A, CD40 ligand, and monocyte chemoattractant protein-1 - predict recurrent stroke and other vascular events among lacunar stroke patients. The project will also determine whether these markers predict which people will respond best to dual antiplatelet therapy with clopidogrel and aspirin, as well the relationship to cognitive function.


METHODS
plan Multivariable Cox proportional hazard regression modeling will be used to estimate hazard ratios for the effect of marker levels on risk of recurrent stroke and other outcomes after adjusting for additional potential risk factors, including age, gender, ethnicity, treatment arm, and traditional stroke risk factors. Interactions between marker levels and treatment assignment for both arms of the SPS3 study will be assessed. Observations will be censored at the time of last follow-up visit.


CONCLUSIONS
LIMITS represents an efficient approach to the identification of novel inflammatory biomarkers for use in risk prediction and treatment selection in patients with small vessel disease.
Elkind
M S V
MS
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA. mse13@columbia.edu
Luna
J M
JM
Coffey
C S
CS
McClure
L A
LA
Liu
K M
KM
Spitalnik
S
S
Paik
M C
MC
Roldan
A
A
White
C
C
Hart
R
R
Benavente
O
O
D001800:Blood Specimen Collection / Q000379:methods; D002097:C-Reactive Protein / Q000378:metabolism; D023201:CD40 Ligand / Q000097:blood; D018932:Chemokine CCL2 / Q000097:blood; D006801:Humans; D007249:Inflammation / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood; D011237:Predictive Value of Tests; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood; D040242:Risk Reduction Behavior; D012449:Safety; D000685:Serum Amyloid A Protein / Q000378:metabolism; D020521:Stroke / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D016896:Treatment Outcome
C111835:CCL2 protein, human; D018932:Chemokine CCL2; D015850:Interleukin-6; D047888:Receptors, Tumor Necrosis Factor, Type I; D000685:Serum Amyloid A Protein; D023201:CD40 Ligand; D002097:C-Reactive Protein
Arch Intern Med. 2001 Nov 12;161(20):2474-80
11700160
J Neurol Sci. 1999 Dec 15;171(2):115-20
10581377
N Engl J Med. 2008 Nov 20;359(21):2195-207
18997196
Stroke. 1997 Nov;28(11):2222-9
9368569
Stroke. 2001 Jan;32(1):133-8
11136928
Circulation. 2009 May 5;119(17):2408-16
19364974
N Engl J Med. 2001 Nov 15;345(20):1444-51
11794192
Neurology. 2008 Sep 9;71(11):804-11
18685136
Atherosclerosis. 1999 Nov 1;147(1):49-53
10525124
J Am Coll Cardiol. 2000 Feb;35(2):358-62
10676681
J Cereb Blood Flow Metab. 2008 Sep;28(9):1574-87
18493257
Stroke. 1995 Jan;26(1):30-3
7839393
J Stroke Cerebrovasc Dis. 2004 Sep-Oct;13(5):220-7
17903979
Stroke. 1996 Mar;27(3):415-20
8610305
Neurology. 1978 Aug;28(8):754-62
567291
Blood Press Monit. 2007 Feb;12(1):1-8
17303981
J Gerontol A Biol Sci Med Sci. 1999 Jul;54(7):M357-64
10462168
Circulation. 2004 Feb 17;109(6):726-32
14970107
Circulation. 2001 Nov 6;104(19):2266-8
11696462
Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):3071-8
10591689
Cardiovasc Res. 2002 Feb 15;53(3):642-9
11861035
Stroke. 2007 Jun;38(6):1752-8
17431206
Circulation. 2000 Apr 18;101(15):1767-72
10769275
Stroke. 2001 Nov;32(11):2575-9
11692019
Stroke. 2002 May;33(5):1420-3
11988625
Circulation. 2004 Jul 27;110(4):386-91
15262833
N Engl J Med. 1999 Jan 14;340(2):115-26
9887164
Ann Neurol. 1993 Jun;33(6):568-75
8498836
Stroke. 1987 May-Jun;18(3):545-51
3590244
Stroke. 1998 Feb;29(2):447-53
9472888
Stroke. 1995 Feb;26(2):245-8
7831696
N Engl J Med. 1974 Jun 6;290(23):1275-8
4827627
Arch Intern Med. 2006 Oct 23;166(19):2073-80
17060536
Stroke. 2000 May;31(5):1062-8
10797166
Arch Intern Med. 1993 Mar 8;153(5):619-24
8439224
N Engl J Med. 2003 Mar 20;348(12):1104-11
12646667
Am J Epidemiol. 2001 Jun 15;153(12):1183-90
11415953
Stroke. 2006 Mar;37(3):790-5
16424371
Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1052-6
10764672
Clin Chem. 2003 Apr;49(4):669-72
12651827
Clin Cardiol. 2002 Apr;25(4):143-7
12000070
N Engl J Med. 2003 Mar 27;348(13):1215-22
12660385
Stroke. 2002 Jan;33(1):31-7
11779885
Neurosci Lett. 2002 May 10;324(1):29-32
11983287
Circulation. 2003 Jan 28;107(3):499-511
12551878
Stroke. 2001 Apr;32(4):842-9
11283380
Stroke. 2002 Apr;33(4):982-7
11935048
Am J Epidemiol. 1982 Sep;116(3):496-509
7124717
Atherosclerosis. 2005 Aug;181(2):329-38
16039287
J Biol Chem. 1997 Aug 1;272(31):19569-74
9235962
N Engl J Med. 2001 Jun 28;344(26):1959-65
11430324
Circulation. 2003 Sep 2;108(9):1049-52
12912804
Eur Heart J. 2000 Oct;21(19):1584-90
10988010
Stroke. 1996 Apr;27(4):661-6
8614926
Circulation. 1997 Jul 15;96(2):396-9
9244201
N Engl J Med. 1981 Feb 19;304(8):465-8
7453772
Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1047-51
10764671
J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):211-6
11796771
Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):603-10
11304479
Circulation. 2005 Feb 22;111(7):863-70
15699251
JAMA. 2001 Apr 4;285(13):1719-28
11277826
Stroke. 1991 Feb;22(2):175-81
2003281
Stroke. 1992 Oct;23(10):1434-8
1412580
Stroke. 2005 Jun;36(6):1207-11
15879345
Circulation. 2003 Apr 22;107(15):2016-20
12681999
Circulation. 1998 Aug 25;98(8):731-3
9727541
Neurology. 1999 Jul 22;53(2):337-43
10430423
J Exp Med. 1995 Jul 1;182(1):33-40
7540655
J Immunol Methods. 1998 May 1;214(1-2):1-10
9692853
Stroke. 2003 Jun;34(6):1412-8
12764232
Neurology. 1997 May;48(5):1204-11
9153444
N Engl J Med. 2000 Mar 23;342(12):836-43
10733371
Stroke. 2000 Jun;31(6):1223-9
10835436
Nature. 1998 Jul 9;394(6689):200-3
9671306
Stroke. 1990 Jun;21(6):842-7
2349585
Stroke. 2005 Jun;36(6):1316-29
15879341
Stroke. 2002 Aug;33(8):2072-6
12154265
Inflammation. 1998 Oct;22(5):483-91
9793795